<DOC>
	<DOCNO>NCT02996019</DOCNO>
	<brief_summary>This randomize , 2-part , 2-arm , open-label , parallel-group , multi-center study compare PK etrolizumab administer SC AI ( test device ) PFS-NSD ( reference device ) healthy participant . The study comprise pilot cohort estimate geometric mean ratio ( GMR ) variability maximum observed concentration ( Cmax ) area concentration-time curve ( AUC ) confirm determine sample size pivotal cohort . The pivotal cohort demonstrate exposure comparability Cmax , AUC hour 0 last measurable concentration ( AUClast ) , AUC extrapolate infinity ( AUC0-inf ) , value single dose etrolizumab administer subcutaneously either AI PFS-NSD .</brief_summary>
	<brief_title>A Study Investigate Comparability Pharmacokinetics Etrolizumab Administered Subcutaneously ( SC ) Prefilled Syringe With Needle Safety Device ( PFS-NSD ) Auto-injector ( AI )</brief_title>
	<detailed_description />
	<criteria>Within body mass index ( BMI ) range 18.0 30.0 kilogram per square meter ( kg/m^2 ) , inclusive In good health , determine clinically significant finding medical history , physical examination , 12lead electrocardiogram ( ECG ) , vital sign Females nonpregnant , nonlactating , either postmenopausal ( least 12 month nontherapyinduced amenorrhea ) , surgically sterile ( e.g. , tubal ligation , hysterectomy ) least 90 day prior enrolment , agree remain abstinent use highly effective method contraception least 24 week study drug administration Males either sterile agree remain abstinent use highly effective method contraception least 24 week study drug administration . Male participant refrain sperm donation Checkin ( Day 1 ) 24 week follow study drug administration Any prior treatment etrolizumab anti integrin agent ( include natalizumab , vedolizumab , efalizumab ) Any prior treatment antimucosal addressin cell adhesion molecule 1 ( antiMAdCAM1 ) agents Any prior treatment rituximab Received intravenous ( IV ) corticosteroid within 30 day prior Screening Use agent deplete B T cell ( e.g. , alemtuzumab , rituximab visilizumab ) within 12 month prior randomization Any prior immunosuppressive agent ( include cyclosporine , tacrolimus , sirolimus , mycophenolate mofetil [ MMF ] ) Chronic nonsteroidal anti inflammatory drug ( NSAID ) use Use prescription medications/products within 14 day prior Check ( Day 1 ) History demyelinate disease Neurological condition diseases History cancer History alcoholism drug addiction within less ( &lt; ) 1 year prior screen History active latent tuberculosis ( TB ) , regardless treatment history History recurrent opportunistic infection and/or history severe disseminate viral infection Positive human immunodeficiency virus ( HIV ) antibody Any current recent sign symptom infection Pregnant lactating Hospitalized within 4 week prior screen History organ transplant Presence skin rash screen history skin disorder Tattoos , scar , chronic rash , sunburn area designate injection site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>